An overview of a case of SLK treated with complete ocular lavage facilitated by an irrigating eyelid retractor.

The lenses have been shown to filter up to 97% of blue, red, and amber light and allows over 70% of soothing green light through.

Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody.

From schools for blind individuals to early intervention services, families have options to help prepare their children with visual impairments for adulthood.

An inside look into a retrospective study conducted from 2019 to 2023 that aimed to assess the effectiveness of treatment and prevention of the progression of uncomplicated acquired myopia through physiotherapeutic methods.

Catch up on what happened in optometry during the week of September 9-September 13.

The study found that visual acuity was 0.53 lines higher in the CureSight participant group than those treated with patching.

Abnormalities in the amygdala causing eye contact avoidance, and dorsal visual stream dysfunction remain some of the theories regarding autism and poor eye tracking.

The study also found lengthy eye examination and eyewear purchase cycles, with averages of 21 and 24 months respectively.

EyeCon 2024 will be running from September 27-28 in Fort Lauderdale, Florida.

The study, conducted in July 2024, reported decreases in all areas of practice performance, including revenue, staff retention, and patient acquisition and retention.

The Finnish company's new device sports a universal adapter and rebound tonometry technology.

The FDA and Palatin agreed on a clear regulatory path for PL9643 NDA submission in DED. The company hopes to start patient enrollment to start in the fourth quarter of calendar year 2024.

Las Vegas, Nevada is where the latest in eyewear and fashion will meet a focus on education.

By identifying progressive GA earlier, primary eye care providers can make timely referrals and save patients’ visual function.

The National High Traffic Safety Administration states that “nighttime driving is inherently challenging due to decreased visibility."

Catch up on what happened in optometry during the week of September 2-September 6.

Resources available during the month include a seminar series and course bundles.

Young will be aiding in expanding real-world evidence programs to promotion the adoption of Brightstar’s BrightMEM corneal allograft for the treatment of limbal stem cell deficiency and persistent epithelial defects.

Living a long life and preserving eye health can go hand in hand.